Sam blends considerable international legal experience with expertise in the biotechnology and molecular biology fields.
Sam works for clients ranging from universities and spin-out companies to large international corporations. He has a particular interest in biopharmaceuticals, including engineered antibodies, antibody-drug conjugates, and immuno-oncology, as well as medical devices.
He has extensive experience in advising on patentability and freedom-to-operate issues, filing strategies, and the drafting and prosecution of local and international patent applications in the bioscience and biomedical fields. He has also advised on patent term extensions and supplementary protection certificates for pharmaceuticals in Europe and elsewhere.
Sam conducted his masters research in embryology in the Reproductive Technologies Group of the Crown Research Institute AgResearch, and went on to conduct further research in the Group. During this time, he developed broad experience in assisted reproductive technologies, sub-cloning, mammalian cell culture, epigenetics, and recombinant protein production. Sam joined the patent profession in New Zealand in 2001, and then spent 12 years working in Europe as a Chartered UK and European patent attorney, before returning to AJ Park in 2019.
Sam's experience working as a qualified attorney in New Zealand and Australia, together with his experience of European and UK practice, provides him with a strong international perspective on patent drafting and prosecution. As a reflection of this, in 2016, Sam was chosen to be a member of one of the examination committees that sets and assesses the European qualification examination for candidates wishing to become professional representatives before the European Patent Office.
- BSc (Biology & Chemistry), University of Waikato (1997)
- MSc (Hons) (Biology), University of Waikato (1999)
- Registered Patent Attorney (New Zealand & Australia)
- Chartered UK & European Patent Attorney
Sam Pearson's insights
Article \ 14 Nov 2022
The launch: The Unitary Patent and the Unified Patent Court
Significant changes are being made to the European patent system, and they will impact all European patent holders. In this article, we cover opting out during the sunrise period, what European patent holders need to consider, and more importantly, what they need to action.